Fortem Financial Group, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Fortem Financial Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$573.97 - $724.32 $91,835 - $115,891	-160 Reduced 16.34%	819 $564,000
Q2 2022 Jul 25, 2022	SELL	$548.35 - $738.84 $2.03 Million - $2.74 Million	-3,702 Reduced 79.09%	979 $579,000
Q1 2022 Apr 27, 2022	BUY	$595.12 - $698.43 $476,096 - $558,744	800 Added 20.61%	4,681 $3.27 Million
Q4 2021 Jan 20, 2022	BUY	$543.48 - $670.97 $22,826 - $28,180	42 Added 1.09%	3,881 $2.45 Million
Q3 2021 Oct 15, 2021	BUY	$574.03 - $680.96 $60,847 - $72,181	106 Added 2.84%	3,839 $2.32 Million
Q2 2021 Jul 14, 2021	BUY	$472.8 - $558.54 $612,748 - $723,867	1,296 Added 53.18%	3,733 $2.09 Million
Q1 2021 Apr 20, 2021	BUY	$446.73 - $548.2 $27,697 - $33,988	62 Added 2.61%	2,437 $1.15 Million
Q4 2020 Jan 29, 2021	SELL	$478.3 - $607.98 $59,309 - $75,389	-124 Reduced 4.96%	2,375 $1.15 Million
Q3 2020 Oct 15, 2020	BUY	$544.75 - $658.21 $1.36 Million - $1.64 Million	2,499 New	2,499 $1.4 Million

1,529

84.1M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Fortem Financial Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Fortem Financial Group, LLC with notifications on news.